Determination of the ELISA kits for screening convalescence plasma with high potency of SARS-CoV-2 IgG
10.13303/j.cjbt.issn.1004-549x.2023.03.001
- VernacularTitle:新冠感染者康复期血浆中高效价新冠病毒IgG抗体检测的ELISA试剂盒筛选
- Author:
Zhijun ZHOU
1
;
Lu FENG
1
;
Shenglan YUE
1
;
Yan PENG
1
;
Bin GAO
1
;
Deiming JI
1
;
Juan LI
1
;
Kejin CHEN
1
;
Lianzhen LIN
1
;
Cesheng LI
1
;
Yong HU
1
;
Taojing LI
2
Author Information
1. Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd., Wuhan 430207, China
2. Chengdu Rongsheng Pharmaceuticals Co., Ltd.
- Publication Type:Journal Article
- Keywords:
SARS-CoV-2;
original strain;
variant strain;
ELISA-IgG potency;
convalescent plasma;
neutralizing antibody potency;
qualified rate of plasma collection
- From:
Chinese Journal of Blood Transfusion
2023;36(3):199-203
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To determine the ELISA kit for screening convalescence plasma with high potency of SARS-CoV-2 IgG by comparing and analyzing the plasma detection results of convalescent plasma collected in different periods via ELISA kits from two manufacturers and the results of mixed plasma with different potency via pseudovirus neutralization experiments. 【Methods】 Two ELISA kits from different manufacturers(named A, B) were used to detect the plasma of 269 convalescent patients collected from Feb.2020~Jan.2022. The correlation and concordance rate of the two results were analyzed to determine the kit preliminarily. According to the titers of diluted series of standard of the preliminary selected kit, 5 mixed plasma samples (G4-G128) with different potency were prepared. The correlation of ELISA IgG results of product A/B, as well as the pseudovirus neutralization test of the original strain, Omicron mutant BA.1 and BA.2 strains were analyzed. Combined with the outside-well dilution mode of the strongly positive samples, the kit for high potency of SARS-CoV-2 IgG screening was determined. 【Results】 When the internal control reference B2 was used as the standard, the detection sensitivity of product A and B was 1∶32 vs 1∶8; the detection sensitivity of product A was 4 times that of product B. The correlation Pearson r between the results given by two kits was 0.944 1(P<0.000 1). Product B with low sensitivity was primarily selected as an alternative kit. The ELISA IgG results of samples from mixed plasma showed that the order of correlation r between product A and B was 0.988. The correlation r between product A and neutralization antibody potency of the three viruses was original strain (0.978)>BA.2(0.970)>BA.1(0.799); the order of correlation r between ELISA IgG results of product B and neutralization antibody potency of the three viruses was original strain(0.994)>BA.2(0.968)>BA.1(0.804). If twice-diluted B2 was taken as the excellent standard, 55.4% of product B met the criterion, while 47.2% of product A met.For positive plasma with high IgG potency, the product B kit required a lower dilution of the sample, which was more convenient to operate. 【Conclusion】 Both of the ELISA IgG kit from product A and B can be used to screen IgG antibodies of SARS-CoV-2, while product B is more suitable for screening positive plasma with high IgG potency.
